WuXi STA, a subsidiary of WuXi AppTec, continued its expansion march with the opening of the Chinese CDMO’s first high-potency oral drug production plant located on the WuXi City campus near Shanghai.
The facility is another stake in the ground for WuXi STA, which has been focused on expanding its drug production capacity for the development and manufacturing of high-potency active pharmaceutical ingredients (HPAPIs) ranging from preclinical to commercial uses.
The latest plant features multiple formulation processes that include wet and dry granulation, tablet compression and coating, and capsule filling capacity of 400 million tablets and 200 million capsules a year.
“As our global partners and customers seek accelerated pathways for new drug development, WuXi STA is committed to further enhancing our integrated platform to enable more healthcare breakthroughs that benefit patients worldwide,” Minzhang Chen, Ph.D., co-chief executive of WuXi AppTec and chief executive of WuXi STA, said in a statement.
Additionally, the company said it will open a new high-potency sterile parenteral production plant on the WuXi campus in the third quarter next year.
In the last few months, work was underway to build a new pharmaceutical manufacturing campus in Delaware and an HPAPI plant at its Changzhou site in Jiangsu, China, that has reactors ranging from 250 liters to 3,000 liters in capacity.
In 2021, WuXi STA opened its first Europe-based drug product manufacturing facility in Couvet, Switzerland, for tablet and capsule commercial manufacturing and packaging capabilities.